Peer AI offers an agentic AI platform that generates and manages complex regulatory documents—such as protocols, clinical study reports, IND applications, investigator’s brochures, and plain-language summaries—while allowing medical writers to intervene at key control points. The system deploys specialized AI agents (data-source, authoring, style, and post-processing) within an intuitive interface to ensure accuracy, compliance, and consistency across more than 200,000 pages typically required for drug approval. Top-20 pharmaceutical companies and emerging biotechs are using the product to cut documentation drafting times by 55–94%, shrinking CSR preparation from 40 to 17 working days and reducing protocol turnaround from 6-8 weeks to one week. In the first three quarters of 2025, daily active usage tripled and overall platform volume grew six-fold, underscoring rapid adoption. Addressing an estimated $15 billion market, the company plans to invest in further product development and commercial expansion. Founded by industry veterans and headquartered in San Francisco, Peer AI has secured $12.1 million in venture funding to date.

Total raised

$12M

Funding rounds

1

Latest round

Equity

Latest activity

Oct 2025